What IBS Actually Is

IBS affects approximately 11% of the global population, with the highest rates in developed nations. In Australia, Better Health Victoria estimates around one in five Australians experiences IBS symptoms, including bloating, abdominal pain, constipation, diarrhoea, or alternating patterns of both. It is classified as a disorder of gut-brain interaction. Meaning the problem involves both the gut itself and the signalling between gut and brain, rather than a structural or inflammatory disease. This is why scans and blood tests often come back normal. The disorder is functional and neurochemical, not anatomical.

What the diagnostic criteria do not capture is that IBS consistently presents with measurable gut microbiome disruption. A 2025 narrative review in Frontiers in Immunology, covering the gut microbiota in IBS, found that there are clear differences in microbiome composition and diversity between IBS patients and healthy controls. A 2024 cross-cohort metagenomic study totalling 9,204 samples identified the first cross-geographically reproducible IBS microbial signature. Meaning the microbiome disruption in IBS is consistent enough to be detected across different countries and populations. It is not random variation. It is a pattern.

IBS is not in your head. But it may be in your gut bacteria. The two are connected by the same gut-brain axis that governs both digestion and mood.

How the Microbiome Drives IBS Symptoms

The gut microbiome modulates IBS symptoms through four mechanisms, as identified in the 2025 Frontiers in Immunology review: the epithelial barrier, mucosal immunity, microbial metabolites including short-chain fatty acids and bile acids, and gut-brain signalling. Each of these is directly affected by microbiome composition. A microbiome low in SCFA-producing bacteria produces less butyrate, weakening the epithelial barrier and reducing immune regulation. Disrupted bile acid metabolism affects gut motility, explaining the constipation-diarrhoea alternation that characterises mixed-type IBS.

Research published in PMC from Western Sydney University, studying 90-day fibre interventions in IBS patients, found that baseline gut microbiome diversity significantly influenced response to fibre intervention. Patients with normal microbiome diversity showed significant improvements to IBS symptom scores and quality of life. Those with low diversity showed less benefit. The microbiome is not just a bystander in IBS. It is the primary determinant of how the gut responds to treatment.

1 in 5 Australians experience IBS symptoms, per Better Health Victoria. Most manage rather than resolve. The gut microbiome research suggests the resolution path has been largely overlooked.

What Works, and What Does Not

Low-FODMAP diets reduce fermentable carbohydrate intake and consistently relieve IBS symptoms in the short term. The problem is that low-FODMAP diets also reduce prebiotic fibre intake, which over time depletes the beneficial bacteria the gut needs. The 2025 Frontiers in Immunology review noted that dietary approaches, probiotics, and prebiotics show variable benefit, with effects that are strain- and context-dependent. Low-FODMAP is symptom management, not microbiome restoration.

The more productive long-term approach is building microbiome diversity. A 2024 meta-analysis of 20 randomised controlled trials covering 3,011 IBS patients found that probiotics improved global IBS symptoms better than placebo, with shorter treatment durations of four weeks or less showing better results. The best outcomes come from combining microbiome-restoring strategies with consistent prebiotic fibre to sustain the beneficial bacteria once introduced.

Managing IBS symptoms is not the same as addressing IBS causes. The microbiome evidence points toward the cause. Consistent prebiotic fibre is the most tractable daily input.

A Note on Soluble Fibre and IBS

Not all fibre is suitable for IBS. High-FODMAP fibres can worsen symptoms in people who are sensitive. Soluble prebiotic fibre, particularly partially hydrolysed varieties that ferment slowly and produce minimal gas, are better tolerated and more beneficial for microbiome diversity without triggering the bloating associated with high-FODMAP intake.

DULCI contains 7g of clinically studied prebiotic fibre per scoop, an excellent source of fibre by the regulated standard. Soluble fibre, not insoluble. Slowly fermented, not rapidly gas-producing. It dissolves in hot or cold liquid. It supports the gut microbiome environment that IBS consistently disrupts.

If IBS has been managed but not resolved, the microbiome is worth addressing directly. The symptoms are the signal. The gut bacteria are the source.

Feed the source and the signal quiets.